Lucentis vs. Avastin Cost Debate Resurfaces With Release Of Medicare Payment Data
This article was originally published in The Pink Sheet Daily
Ophthalmologists are among the highest billing specialties listed in the Medicare Part B physician payment data, with Genentech’s Lucentis a strong driver of cost.
You may also be interested in...
Developing alternatives to the ASP-based reimbursement system for Medicare Part B drugs may become increasingly important to ensure the program will benefit from lower-cost biosimilars, Georgetown’s Jack Hoadley points out.
In Brief: Amarin Perseveres With Vascepa Outcomes Trial, Cochrane Review Reignites Lucentis Cost Debate
Plus Acura’s own appeal on abuse-deterrent opioid, TG Therapeutics gets FDA buy-in for ublituximab accelerated approval plan, and Amgen presents more analysis supporting heart failure drug ivabradine after Servier’s failed outcomes trial.
Analysis of money spent on the treatments for wet age-related macular degeneration offers an argument for least costly alternative policy as a way of cutting health care spending.